Cannabidiol (CBD) (INN) is one of at least 113 active cannabinoids identified in cannabis. It is a major phytocannabinoid, accounting for up to 40% of the plant’s extract. CBD is considered to have a wide scope of potential medical applications - due to clinical reports showing the lack of side effects, particularly a lack of psychoactivity (as is typically associated with ∆9-THC).
- government licensed operation
- all products are made from legal EU hemp varieties
- a guarantee of natural phytocannabinoid content
This is an updated version (January 2017) of the position paper of the European Industrial Hemp Association (EIHA) on reasonable regulation of cannabidiol (CBD) in food, cosmetics, as herbal natural medicine and as medicinal product, first published in October 2016.